Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 362 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control Group - Vehicle Safety Clear all
Completed Phase 3 Interventional

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, Vehicle Spray
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 1 Interventional

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

NCT06137157
View directory record Official record
Conditions
Netherton Syndrome
Interventions
ATR12-351
Drug
Lead sponsor
Azitra Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Palo Alto, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Test Article A, Test Article B, Placebo, KXL medical device system
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 5, 2026, 4:24 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

NCT04154293
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
Isotretinoin, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
9 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional

An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations

NCT06538662
View directory record Official record
Conditions
Ocular Redness, Eye Irritation
Interventions
FID 123320 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
5 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Azusa, California • Newport Beach, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

NCT03916042
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

NCT03664739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDp-120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
25
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Twelve Week Safety and Efficacy Study in Rosacea

NCT01784133
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
omiganan, placebo
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Sep 5, 2026, 4:24 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

NCT01830348
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA on Human Volunteers

NCT01397604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, Squalene
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 5, 2026, 4:24 PM EDT
Active, not recruiting Phase 1 Interventional

Regulatory T Cells for Amyotrophic Lateral Sclerosis

NCT05695521
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK0803, Excipient
Biological · Other
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 5, 2026, 4:24 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

NCT00353964
View directory record Official record
Conditions
Ocular Inflammation
Interventions
rEV131, Prenisolone sodium phosphate 1.0%, rEV131 vehicle
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2006 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

NCT00742391
View directory record Official record
Conditions
Actinic Keratoses
Interventions
PEP005 (ingenol mebutate) Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Mesa, Arizona • Denver, Colorado • Kissimmee, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

NCT03691649
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

NCT01039584
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

NCT02908620
View directory record Official record
Conditions
Anesthesia
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
Combination Product · Drug
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355458
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Clinton Township, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT01025635
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam 15%, Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Fremont, California • Santa Monica, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 5, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 5, 2026, 4:24 PM EDT